A Phase 2, Randomized, Double-blind, Placebo-controlled Trial of Fosamprenavir-Sodium Alginate Administered Orally for 8 Weeks to Patients With Proton Pump Inhibitor Refractory Gastroesophageal Reflux Disease

The goal of this clinical trial is to learn if study drug Fosamprenavir-Sodium Alginate (FOS-SA) administered orally improves symptoms for Proton Pump Inhibitor (PPI)-refractory Gastro Esophageal Reflux Disease (GERD).
The main questions it aims to answer are:
1. Does FOS-SA significantly improve heartburn severity over the 8-week treatment period
2. Does FOS-SA significantly improve regurgitation frequency over the 8-week treatment period
3. Does FOS-SA significantly improve symptoms of persistent GERD over the 8-week treatment period
Researchers will compare FOS-SA to a placebo (a look-alike substance that contains no active drug) to see if FOS-SA works to treat PPI-refractory GERD.
Participants will:
1. Take FOS-SA or placebo every day BID (twice a day) for 8 weeks
2. Visit the Adult Translational Research Unit (ATRU) seven times for consenting, screening, and checkups and tests
3. Keep a daily diary of their symptoms of persistent GERD

Start Date01 Jan 2027

Sponsor / Collaborator

Medical College of Wisconsin

NCT04383262

/ RecruitingPhase 2IIT

A 12-Week Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Efficacy of Oral Fosamprenavir for Laryngopharyngeal Reflux

Laryngopharyngeal Reflux (LPR) is a common condition that causes symptoms like chronic cough, throat clearing, hoarseness, and trouble swallowing. If not treated, LPR can lead to long-term throat damage and may increase the risk of throat cancer. More than 20% of the people in the United States are estimated to have LPR, yet there is no effective medication approved to treat it. Drugs called proton pump inhibitors (PPIs) are often used to treat LPR, even though they were designed for stomach acid problems. These medications reduce acid but do not stop reflux from happening, so they often do not help LPR patients. Despite poor results, PPIs are widely prescribed, are very costly, and can cause side effects.
Research shows that a digestive enzyme called pepsin plays a key role in LPR. Pepsin can damage the throat and voice box even when acid is not present. Laboratory studies found that certain HIV medications can block damage caused by pepsin. People taking these medications for HIV appear to have a much lower rate of LPR. This study will test fosamprenavir, an FDA-approved HIV drug, as a treatment for LPR. We will conduct a 14-week, double-blind, placebo-controlled clinical trial in patients with LPR who did not improve with standard treatment. Participants will receive either fosamprenavir or placebo, randomly, and symptoms will be measured before and after treatment using standard questionnaires and daily symptom tracking.
Because there is no effective medical treatment for LPR. this study aims to test a safe, existing drug that targets the underlying cause of the disease.

Start Date15 Jul 2026

Sponsor / Collaborator

Medical College of Wisconsin

EUCTR2016-005043-16-BE

/ CompletedPhase 4IIT

Impact of stomach motility on the gastrointestinal behavior of fosamprenavir in healthy volunteers

Start Date18 Feb 2020

Sponsor / Collaborator-

100 Clinical Results associated with Fosamprenavir calcium

100 Translational Medicine associated with Fosamprenavir calcium

100 Patents (Medical) associated with Fosamprenavir calcium

951

Literatures (Medical) associated with Fosamprenavir calcium

01 Aug 2026·VETERINARY JOURNAL

Diagnostic utility of serum amyloid A, procalcitonin and hematology-derived inflammatory indices in cats naturally infected with feline panleukopenia virus

Article

Author: Taşdemir, Mine ; Pekmezci, Didem

Feline panleukopenia virus (FPV) infection is a highly contagious and potentially fatal disease of cats, characterized by intestinal injury, bone marrow suppression and systemic inflammatory alterations. This study evaluated the diagnostic utility of serum procalcitonin (PCT), serum amyloid A (SAA), selected biochemical variables and hematology-derived inflammatory indices in cats naturally infected with FPV. Fifty-nine cats were enrolled between February 2024 and December 2025, including 28 cats with naturally occurring FPV infection and 31 healthy controls. FPV infection was diagnosed using a fecal FPV antigen rapid test. Complete blood count variables were recorded, and serum concentrations of PCT, SAA, albumin (ALB), total protein, globulin, magnesium and glucose (GLU) were measured. Hematology-derived inflammatory indices, including neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, derived neutrophil-to-lymphocyte ratio, aggregate index of systemic inflammation (AISI), systemic inflammatory response index (SIRI) and systemic immune-inflammation (SII) index, were calculated. Cats with FPV infection had significantly higher SAA concentrations than healthy cats, with median values of 174.05 µg/mL and 5.00 µg/mL, respectively. Serum GLU was also higher in the FPV group, whereas ALB concentration was lower. White blood cell, neutrophil, lymphocyte, monocyte, eosinophil, basophil and platelet counts differed significantly between groups. Several inflammatory indices, particularly AISI and SIRI, showed strong diagnostic performance, with area under the receiver operating characteristic curve values of 0.92 and 0.91, respectively. DeLong analysis showed no significant difference between the diagnostic performance of these indices and SAA. In contrast, serum PCT did not show diagnostic utility and was not correlated with any biochemical variable. These findings indicate that SAA is an excellent diagnostic biomarker in cats naturally infected with FPV. In addition, selected hematology-derived inflammatory indices, particularly AISI and SIRI, may serve as practical and cost-effective adjunctive tools derived from routine complete blood count data. Serum PCT appears to have limited value in the diagnostic assessment of primary viral FPV infection.

01 Jul 2026·JOURNAL OF MEDICAL VIROLOGY

Favipiravir Is Associated With Reduced 28‐Day Mortality in Severe Fever With Thrombocytopenia Syndrome: A Multicenter Propensity Score–Matched Study

Article

Author: Deng, Xiangjun ; Zhang, Jiankang ; Hu, Lifen ; Wei, Liangchen ; Ye, Ying ; Ding, Xiaobo ; Pan, Zhi Ping ; Zhang, Chun ; Rao, Jianguo

ABSTRACT:

This study aimed to evaluate the efficacy of add‐on favipiravir to standard ribavirin therapy in reducing 28‐day mortality among patients with SFTS and to identify clinical subgroups that may derive greater benefit. This multicenter retrospective study included adults with laboratory‐confirmed SFTS from four hospitals (2022–2025). All patients received standard ribavirin therapy, while patients in the FPV group additionally received favipiravir at admission. Propensity score matching ensured balance in baseline characteristics. Survival was analyzed using Kaplan–Meier curves and Cox models with subgroup interaction analyses. Among 1199 eligible patients, the 28‐day mortality was 20.6%. The FPV group showed lower 28‐day mortality than the non‐FPV group (14.1% vs. 24.5%). FPV treatment was associated with lower 28‐day mortality across all baseline viral load categories, with the most pronounced association observed in patients with low viral load (< 10 5 copies/mL), and a weaker but still significant association in those with high viral load (≥ 10 7 copies/mL). A significant association was also observed in patients with onset‐to‐admission interval ≥ 5 days and in those aged < 70 years. A trend toward lower mortality was also observed in patients with an onset‐to‐admission interval < 5 days and in those aged ≥ 70 years, although the associations were not statistically significant. FPV treatment was associated with reduced mortality regardless of corticosteroid or intravenous immunoglobulin use. In this study, FPV therapy was associated with reduced 28‐day mortality regardless of baseline viral load or the interval of onset‐to‐admission. These findings support initiating FPV therapy promptly after admission without waiting for viral load results.

01 Jul 2026·JOURNAL OF FELINE MEDICINE AND SURGERY

Antibody responses to inactivated (adjuvanted) and attenuated (non-adjuvanted) feline panleukopenia virus vaccination, including in different injection sites

Article

Author: McDonald, Mike ; Martin, Caitlin ; Hosie, Margaret J ; Westman, Mark E ; Parr, Yasmin ; Atkin, Nerida ; Weir, William ; Meggiolaro, Maira Nascimento ; Norris, Jacqueline M ; Malik, Richard ; Hall, Evelyn ; Pan, Stefanie ; Nakamura, Mizuho ; Dunbar, Dawn ; Hughes, David ; Wuestner, Eliza ; Hajjar, Rabia

Objectives:

Vaccines have traditionally been administered to cats into the interscapular subcutaneous region (‘scruff’) for ease of restraining the cat while the vaccine is injected. Concern about feline injection-site sarcomas (FISSs) has prompted recommendations to use distal sites such as the hindlimb or tail, but evidence of adequate immune response at these sites is limited. This field study evaluated the antibody response to feline panleukopenia virus (FPV) in kittens vaccinated with one of two commercial vaccines, injected at different sites.

Methods:

An inactivated (killed), adjuvanted pentavalent vaccine (Fel-O-Vax 5; Boehringer Ingelheim Animal Health Australia) was injected subcutaneously into the scruff, left distal hindlimb or proximal tail. A modified-live virus (attenuated [MLV]), non-adjuvanted trivalent vaccine (Feligen RCP; Virbac Animal Health Australia) was given into the scruff only. For the latter, an inactivated, adjuvanted monovalent feline leukaemia virus vaccine was administered concurrently into the contralateral scruff, left distal hindlimb or proximal tail. Only one FPV-containing vaccine was administered to each cat/kitten: either the inactivated vaccine given in one of the three different anatomical regions or the MLV vaccine given into the scruff only. Cats were re-vaccinated in the same site and using the same vaccine type. Kittens were randomly allocated into study groups according to order of recruitment. Kittens were sampled at four time points over 12 months (T0, T1, T2 and T12). Protective FPV antibody titres were determined by haemagglutination inhibition (HI; negative <1:32, positive ⩾1:32).

Results:

Samples from 100 kittens (T0, T1, T2) and 77 returning adult cats (T12) were available for FPV antibody testing (median age of kittens at T0 was 13 weeks, range 7–16). Eight kittens (8%) were found to be HI-positive at T0. Protective titres did not differ significantly among the three injection sites for the inactivated vaccine. Linear modelling demonstrated that antibody titres were higher in kittens given the MLV vaccine compared with kittens given the inactivated vaccine at T1 ( P = 0.006) and T12 ( P = 0.001). However, the proportion of kittens protected in each group (MLV vaccine vs inactivated vaccine) was the same. For most kittens (91%), a single vaccination was sufficient to produce protective antibody levels, irrespective of whether they were given the MLV (scruff) or inactivated vaccine (at any site). Age and sex had no effect on antibody titres after vaccination. Two kittens (2%) failed to achieve protective titres after two doses of vaccine and required re-vaccination between 16 and 18 weeks. Inexplicably, one (1%) adult cat lacked a protective antibody titre response at T12 despite earlier seroconversion.

Conclusions and relevance:

Both inactivated and MLV vaccines induce protective titres against FPV. Although most kittens aged above 7 weeks are protected 1 month after a single vaccination, some require re-vaccination to develop protection. Some kittens require a final vaccination at 16 weeks or older and a booster 6–12 months later to develop robust protective titres. Comparable FPV antibody responses are elicited when inactivated vaccines are administered into the scruff, left distal hindlimb or proximal tail. Notably in this study, the MLV vaccine tended to produce higher antibody titres. These results support evidence-based recommendations on vaccination site selection to mitigate FISS risk in jurisdictions where this condition is prevalent.

News (Medical) associated with Fosamprenavir calcium

23 Jul 2026

·allsci.com

N-Zyme Bio secures USD 4.6m Series A to advance pepsin-targeted reflux therapies

Delaware-based N-Zyme Biomedical, a clinical-stage biotechnology company developing pepsin-targeted therapies for reflux disease, has closed a Series A financing round raising approximately USD 4.6 million. The funding will support the company’s Phase II clinical programs in laryngopharyngeal reflux (LPR) and proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). The round drew participation from a mix of healthcare professionals, entrepreneurs, a venture capital group, and strategic investors, though no lead investor was named. Proceeds will fund the ongoing Phase II trial in LPR, the planned Phase II study in PPI-refractory GERD, along with regulatory, manufacturing, and business development activities. Prior to this round, N-Zyme relied on non-dilutive funding, including two Falk Medical Research Trust awards, and had already advanced its lead candidate into the clinic, beginning its Phase II LPR trial in June 2026. This marks the company’s first disclosed institutional equity raise. N-Zyme’s platform is built on the premise that pepsin, not just gastric acid, is a primary driver of tissue damage in reflux disease. Pepsin remains partially active even at higher pH levels reached during PPI therapy, and research from the company’s academic origins has shown it can be internalized into epithelial cells and reactivated intracellularly, contributing to persistent symptoms despite acid suppression. N-Zyme’s lead approach repurposes fosamprenavir, an FDA-approved HIV protease inhibitor, based on structural similarities between HIV protease and pepsin, both aspartic proteases. This enzyme therapeutics strategy aims to address an underlying mechanism of tissue injury rather than simply reducing acid output. The company’s lead program is oral fosamprenavir in a Phase II trial for LPR, a condition with no FDA-approved pharmacological treatment. A second Phase II program in PPI-refractory GERD, using a sustained-release oral fosamprenavir-sodium alginate formulation, is planned. An earlier-stage aerosolized formulation for LPR is also in development, with GLP inhalation toxicology studies underway. The drug development funding secured through this biotech Series A funding round is intended to fully capitalize both Phase II programs. N-Zyme Biomedical originated from research conducted at the Medical College of Wisconsin, where the firm’s co-founder and chief scientific officer Nikki Johnston led laboratory work characterizing pepsin’s pathological role in reflux disease and identifying amprenavir’s pepsin-inhibitory activity. The company’s core intellectual property stems from this academic research, with Johnston named as sole inventor on the foundational patent covering HIV protease inhibitors for reflux indications. Vigile, the company’s business co-founder, is himself a patient with LPR. With the financing complete, N-Zyme said it is positioned to advance its clinical programs and pursue additional strategic partnerships, having recently participated in the BIO Investment & Growth Summit to explore further collaboration opportunities. Access the AllSci platform to explore the science behind the news. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2

11 Jun 2026

·allsci.com

N-Zyme repurposing HIV drug fosamprenavir for laryngopharyngeal reflux disease

N-Zyme Biomedical, a clinical-stage company headquartered in Delaware, announced the initiation of a Phase II trial of fosamprenavir for laryngopharyngeal reflux (LPR), marking the first clinical test of a pepsin inhibitor in reflux disease and a direct challenge to the decades-long dominance of acid suppression as the therapeutic paradigm for this condition. The significance lies in the molecule’s mechanism: while proton pump inhibitors (PPIs) and potassium-competitive acid blockers (P-CABs) reduce gastric acid, they do not address pepsin, the proteolytic enzyme that research increasingly implicates as a primary driver of tissue damage in LPR and other extraesophageal reflux manifestations. Fosamprenavir, the molecule N-Zyme is repurposing, is a well-characterized antiretroviral prodrug with an established human safety profile from its prior use in HIV therapy – marketed by ViiV Healthcare/GSK as Lexiva/Telzir. After identifying its function as a pepsin inhibitor, N-Zyme has recently secured patents from both the US Patent and Trademark Office and the Japan Patent Office covering its use in reflux indications. The trial is led by Dr. Nikki Johnston at the Medical College of Wisconsin, who has published extensively on pepsin’s role in LPR pathology. Competitive context The reflux treatment landscape is currently being reshaped by the P-CAB class. Phathom Pharmaceuticals’ Voquezna (vonoprazan) is approved in the US for erosive GERD, non-erosive GERD, and H. pylori eradication, while Sebela Pharmaceuticals’ tegoprazan has an NDA under FDA review with a decision anticipated in January 2027 following positive Phase III TRIUMpH data. Both agents, however, share the same fundamental limitation as PPIs: they suppress acid without targeting pepsin, leaving a subset of patients — particularly those with LPR — without adequate symptom control. Cross-trial comparisons are limited by differences in patient populations and endpoint definitions, but N-Zyme’s pepsin-directed approach is mechanistically distinct from all current approved therapies and any known late-stage pipeline program. LPR, often called “silent reflux,” is characterized by symptoms including chronic cough, hoarseness, and throat clearing, and is notoriously difficult to treat with standard acid-suppressive regimens. The patient population that fails PPIs and P-CABs represents a commercially and clinically meaningful unmet need, though the precise size of the addressable LPR market remains difficult to quantify given chronic underdiagnosis. The Phase II trial is expected to generate efficacy and safety data that will determine whether the pepsin inhibition hypothesis translates into clinical benefit — a question that the field has lacked the tools to answer until now. This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/ Your email address will not be published. Required fields are marked * Comment * Name * Email * Website Privacy Terms About Us Copyright © 2026. AllSci Corp. All rights reserved.

Phase 2Phase 3Drug ApprovalNDA

10 Jun 2026

·www.biospace.com

N-Zyme Biomedical Begins Phase 2 Trial of First Pepsin Inhibitor for Reflux Disease

Company advancing a first-in-class approach to targeting pepsin, with the potential to redefine the standard of care; recently granted patents from the U.S. Patent and Trademark Office and Japan Patent Office, strengthening its intellectual property position WAUWATOSA, Wis. & NEWARK, Del.--(BUSINESS WIRE)-- #Biotech -- N-Zyme Biomedical , a clinical-stage biotechnology company developing a novel class of therapeutics targeting pepsin in reflux disease, today announced the initiation of its Phase 2 clinical trial to evaluate its lead pepsin inhibitor candidate for the treatment of laryngopharyngeal reflux (LPR). The trial represents a key milestone in the development of what is believed to be the first therapeutic approach specifically designed to inhibit pepsin, a primary driver of tissue damage and symptoms in reflux disease. Unlike traditional acid-suppressing therapies, including proton pump inhibitors (PPIs)that do not address non-acidic components of reflux, N-Zyme’s approach is designed to target pepsin directly—addressing a key mechanism underlying persistent and treatment-resistant symptoms. LPR, often referred to as “silent reflux,” remains significantly underdiagnosed and undertreated, with many patients continuing to experience chronic symptoms despite standard therapies. By targeting pepsin, N-Zyme is advancing a differentiated approach with the potential to improve outcomes across a large and underserved patient population. “The initiation of our Phase 2 trial marks an important milestone for N-Zyme and the advancement of a new therapeutic approach in reflux disease,” said Franco Vigile , Co-Founder and Chief Executive Officer of N-Zyme Biomedical. “For decades, the standard of care has focused primarily on acid suppression, despite growing evidence supporting the role of pepsin in disease pathology—particularly in LPR and other extraesophageal manifestations of reflux. We believe targeting pepsin represents a differentiated approach with the potential to redefine how reflux disease is treated and improve outcomes for millions of patients.” Strengthened Intellectual Property Portfolio In parallel with the advancement of its clinical program, N-Zyme recently expanded its intellectual property portfolio with the issuance of patents covering the use of fosamprenavir for the treatment of reflux disease from both the United States Patent and Trademark Office and the Japan Patent Office. These patents provide strategic protection for the use of fosamprenavir and related compounds in reflux indications and further support the company’s position in developing therapies targeting pepsin. About the Phase 2 Trial The Phase 2 clinical trial is designed to evaluate the efficacy and safety of N-Zyme’s pepsin inhibitor candidate, utilizing fosamprenavir, a well-characterized molecule with an established safety profile, in patients diagnosed with laryngopharyngeal reflux. The trial is led by Dr. Nikki Johnston at the Medical College of Wisconsin and is expected to generate data supporting the therapeutic potential of pepsin inhibition. About N-Zyme Biomedical N-Zyme Biomedical is a clinical-stage biotechnology company headquartered in Delaware, United States. The company is developing a novel class of therapeutics designed to inhibit pepsin, with the goal of advancing the treatment of reflux disease and addressing a significant unmet medical need. Contacts Franco Vigile CEO and Co-Founder Franco.vigile@nzymebio.com

Phase 2

100 Deals associated with Fosamprenavir calcium

External Link

KEGG	Wiki	ATC	Drug Bank
D02497	Fosamprenavir calcium	J05AE07	DB01319

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
HIV Infections	United States	ViiV Healthcare Co.	20 Oct 2003

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Herpesviridae Infections	Phase 1	United States	ViiV Healthcare Ltd.	01 Sep 2010
Mycoses	Phase 1	Netherlands	GSK Plc	01 Jan 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00802074 (CTgov)	Not Applicable	-	45	Fosamprenavir+raltegravir (Group A)	watsksyzox = lloobrurvo joknhonzgz (tesvnmqrvm, vhmbkohqlm - ppvyoevisa) View more	-	29 Jan 2016
				Fosamprenavir+raltegravir (Group B)	watsksyzox = hlxccmbfot joknhonzgz (tesvnmqrvm, ckiadyewel - piahjsvfzz) View more
NCT00764465 (CTgov)	Phase 2	-	45	Fosamprenavir+maraviroc (Group A)	pzbgzloqin = hdwqjbptyl ykjqnlljfi (lsadmanvvw, nvlwqczkzy - optjborcrx) View more	-	29 Jan 2016
				Fosamprenavir+maraviroc (Group B)	pzbgzloqin = tddgsrrtaw ykjqnlljfi (lsadmanvvw, aoovdktmpk - fgzwpotjpz) View more
NCT00614991 (CTgov)	Not Applicable	-	44	Fosamprenavir+raltegravir (Group A)	ttiwmghcin = rrodreorgs ybjfzyiupd (hlomamdoug, rkfkihorhf - rhmfxmugfj) View more	-	29 Jan 2016
				Fosamprenavir+raltegravir (Group B)	ttiwmghcin = ooqxvuwkyg ybjfzyiupd (hlomamdoug, uhfchytbui - pwbugzmouq) View more
Pubmed \| Pediatr Infect Dis J	Not Applicable	HIV Infections	-	Fosamprenavir twice-daily	mxivbvvpor(mthigtsior) = igdmxuqnln dirxoiwkpp (tenltwotpp )	-	01 Jan 2014
				Fosamprenavir/ritonavir-containing therapy twice-daily	mxivbvvpor(mthigtsior) = vfzsynjccd dirxoiwkpp (tenltwotpp )
NCT00242216 (CTgov)	Phase 4	Acquired Immunodeficiency Syndrome \| HIV Infections	76	Atazanavir (Atazanavir)	ddewhdcmlw = lphqjiserd moyuanwegf (zkfuwbhgou, cdkgkxehbm - qylkhoariw) View more	-	17 Oct 2013
				Fosamprenavir (Fosamprenavir)	ddewhdcmlw = xpjeesefmv moyuanwegf (zkfuwbhgou, ahejmnmgto - aipqsbiifa) View more
NCT00071760 (CTgov)	Phase 2	HIV Infections	59	FPV+RTV (FPV/RTV BID: 4 Weeks to <6 Months)	ecqwifjmsf(lqnzoigpoa) = tnymymbjhw amqmhxkxco (eespmonnlk, shhcjjkirc - ylvvzuayku) View more	-	23 Aug 2012
				FPV+RTV (FPV/RTV BID: 6 Months to <2 Years)	ecqwifjmsf(lqnzoigpoa) = spfyetxcbz amqmhxkxco (eespmonnlk, lbkttqmwmh - atwbrmgdmb) View more
NCT00884793 (PLUS, CTgov)	Not Applicable	HIV Infections	8	efavirenz+ritonavir+darunavir+raltegravir	gicbwlzlsq = pdzdkihbcc bsvaixzaru (zoduivmiic, prxqywjxnd - nlxrsgbkex) View more	-	23 Jul 2012
NCT00089583 (CTgov)	Phase 2	HIV Infections	110	FPV (FPV Treatment Group)	celqucztwo(zdeotkagyt) = wpszrpkpeg pkfaccjlih (ndztofbrio, uezytsdjqe - fmyjyndbgo) View more	-	21 Jun 2012
				FPV+RTV (FPV/RTV Treatment Group)	celqucztwo(zdeotkagyt) = cxidhyvmbn pkfaccjlih (ndztofbrio, kckydlsxgg - fqvvyysfmd) View more
NCT01010399 (BuLLET, CTgov)	Phase 4	Hypertriglyceridemia \| HIV Infections	36	Lovaza+fosamprenavir+ritonavir	pzdiitmwfb = gxugpcflhw llugwmwgwq (cqvoyccxyj, rfolldwcvm - fbxikjzcfr) View more	-	18 Apr 2012
IAS 12012 \| IAS 22012 \| IAS 32012 \| IAS 42012 \| IAS 52012 \| IAS 62012 \| IAS 72012 \| IAS 82012 \| IAS 92012 \| IAS 102012 \| IAS 112012 \| IAS 122012 \| IAS 132012 \| IAS 142012 \| IAS 152012 \| IAS 162012 \| IAS 172012 \| IAS 182012 \| IAS 192012 \| IAS 202012 \| IAS 212012 \| IAS 222012 \| IAS 232012 \| IAS 242012 \| IAS 252012 \| IAS 262012 \| IAS 272012 \| IAS 282012 \| IAS 292012 \| IAS 302012 \| IAS 312012	Not Applicable	HIV Infections	-	FPV-ritonavir (RTV)-containing ART	zylpzjamfr(qpcgpfuusl) = fcljqqhqlw ivyoizwshn (cajqvgnqlk )	-	01 Jan 2012
				Unboosted FPV	zylpzjamfr(qpcgpfuusl) = vnfnkufviu ivyoizwshn (cajqvgnqlk )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis